Pediatric transplantation: results in solid tumors.

Morris Kletzel*, Brad Hewlett

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Solid tumors are one of the leading causes of disease-related mortality in children today. Although overall survival of children with solid tumors has improved over time, certain high-risk patients continue to respond poorly to conventional therapy. Recent studies have investigated using dose-intensified myeloablative therapy with autologous hematopoietic progenitor cell transplantation (AHPCT) in hopes of eradicating disease and improving the long-term survival of these patients. Results of high-dose therapy with AHPCT have been encouraging in treatment of metastatic neuroblastoma and recurrent Wilms' tumor, but little benefit has been demonstrated with Ewing's sarcoma. In this article, we examine the role of autologous transplant with each solid tumor and discuss some of the recent transplant-related controversies still under debate.

Original languageEnglish (US)
Pages (from-to)260-269
Number of pages10
JournalCurrent hematology reports
Issue number4
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Pediatric transplantation: results in solid tumors.'. Together they form a unique fingerprint.

Cite this